Otilimab
Otilimab
Otilimab (pronounced oh-ti-li-mab) is a monoclonal antibody that is currently being studied for its potential use in the treatment of various autoimmune diseases, including rheumatoid arthritis.
Etymology
The name "Otilimab" follows the World Health Organization's guidelines for the naming of monoclonal antibodies. The "-mab" suffix indicates that it is a monoclonal antibody, while the "otili-" prefix does not have a specific meaning and is used to ensure the name is unique.
Mechanism of Action
Otilimab works by targeting and inhibiting the activity of granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein that plays a key role in the inflammatory process of autoimmune diseases.
Clinical Trials
As of 2021, Otilimab is in Phase III clinical trials for the treatment of rheumatoid arthritis. The trials are being conducted by GlaxoSmithKline, the pharmaceutical company that developed the drug.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Autoimmune disease: A condition in which your immune system mistakenly attacks your body.
- Rheumatoid arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
- Granulocyte-macrophage colony-stimulating factor (GM-CSF): A protein that stimulates the production of white blood cells.
External links
- Medical encyclopedia article on Otilimab
- Wikipedia's article - Otilimab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski